The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms [about 88 pounds]) with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progression to severe COVID-19, including hospitalization or death.
FDA authorizes additional monoclonal antibody for treatment of COVID-19
May 30, 2021
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022